

# Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026

https://marketpublishers.com/r/GF3CC450BF1FEN.html

Date: April 2021

Pages: 180

Price: US\$ 3,000.00 (Single User License)

ID: GF3CC450BF1FEN

#### **Abstracts**

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

"Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026" Report Highlights:

Commercialization Market Potential After Market Launch: > USD 4 Billion

Insight on Key Drugs In Research & Development

Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight

Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies

Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type

Adopted Approaches for Gamma Delta T Cell Therapy

Over the past few years, the idea of immunotherapy of ability to manipulate immune cells in targeting tumor cells is gaining momentum in field of cancer therapeutics. Since then scientists have developed a wide range of potential candidates which has shown encouraging results in the management of cancer. The recent clinical success of chimeric antigen receptor in the management of hematological malignancies has clearly led to the explosion in the field of adoptive cell therapy for cancer. Researchers are currently putting efforts for the translation of this exciting technology in solid tumors and the development of allogeneic off the shelf therapies.



With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.

Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.

The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.

Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.

In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker. In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific



will also emerge as a potential market due to increase in awareness among the population of the region.



#### **Contents**

#### 1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY

- 1.1 Emerging Role of T Cell Based Immunotherapies
- 1.2 Overview to Gamma Delta T Cell Therapy

#### 2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES

- 2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
- 2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
- 2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
- 2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
- 2.5 Gamma Delta T Cell Therapy Vs. Others

#### 3. ROLE OF GAMMA DELTA T CELLS IN CANCER

- 3.1 Gamma Delta T Cells in Cancer Progression
- 3.2 Anti Tumor Activity of Gamma Delta T Cells

#### 4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY

- 4.1 Gamma Delta T Cell as Bispecific Antibodies
- 4.2 CAR Gamma Delta T Cells

# 5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT

- 5.1 ADI-001
- 5.2 LAVA-051
- 5.3 INB-200
- 5.4 TCB002
- 5.5 INB-100
- 5.6 ACE1831
- 5.7 GDX012

# 6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW



- 6.1 By Country
- 6.2 By Company
- 6.3 By Indication
- 6.4 By Phase

# 7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase-I
- 7.4 Phase-II/III

#### 8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA

- 8.1 Role of Gamma Delta T Cells in Leukemia
- 8.2 Ongoing Clinical Research in Acute Leukemia
- 8.3 Clinical Trials in Chronic Lymphocytic Leukemia
- 8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia

#### 9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER

- 9.1 Overview
- 9.2 Ongoing Research & Development
- 9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

#### 10. GAMMA DELTA T CELLS IN BREAST CANCER

- 10.1 Overview
- 10.2 Ongoing Research & Development in Breast Cancer
- 10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

#### 11. GAMMA DELTA T CELLS IN COLORECTAL CANCER

- 11.1 Function of Gamma Delta T Cells in Colorectal Cancer
- 11.2 Ongoing Clinical Trials in Colorectal Cancer
- 11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

#### 12. GAMMA DELTA T CELLS IN PANCREATIC CANCER



- 12.1 Overview
- 12.2 Ongoing Research & Development in Pancreatic Cancer
- 12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer
- 13. Current Clinical Research in Other Cancers

#### 13.1 ONGOING CLINICAL TRIALS IN NEUROBLASTOMA

- 13.2 Ongoing Clinical Trials in Glioblastoma
- 13.3 Ongoing Research & Development in Head & Neck Cancer

#### 14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW

- 14.1 Current Market Scenario
- 14.2 Market Potential of Gamma Delta T Cell Therapy Market

#### 15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS

- 15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
- 15.2 Gamma Delta T Cell Therapy Market: Challenges

#### 16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS

#### 17. COMPETITIVE LANDSCAPE

- 17.1 Acepodia
- 17.2 Adaptate Therapeutics
- 17.3 Adicet
- 17.4 Cytomed Therapeutics
- 17.5 Gadeta
- 17.6 GammaDelta Therapeutics
- 17.7 IN8bio
- 17.8 Kiromic Biopharma
- 17.9 Lava Therapeutics
- 17.10 Takeda Pharmaceuticals
- 17.11 TC Biopharm



### **List Of Figures**

#### **LIST OF FIGURES**

Figure 1-1: History	√ of T	cell Based	<b>Immunotherapy</b>
---------------------	--------	------------	----------------------

- Figure 1-2: Gamma Delta T cell Therapy
- Figure 1-3: Stimulants of Gamma Delta T Cells
- Figure 2-1: Limitation of CAR T Cell Therapy
- Figure 2-2: Limitations of TIL
- Figure 2-3: Limitations of Monoclonal Antibodies
- Figure 2-4: Drawback of Chemotherapeutic Drugs
- Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
- Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
- Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
- Figure 4-1: Gamma Delta T Cell Bispecific Antibodies Mechanism of Action
- Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
- Figure 4-3: CAR ?? T Cells Mechanism of Action
- Figure 5-1: ADI-001 Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-2: DRI Cell Therapy Initiation & Completion Year of Phase-I Clinical Trial
- Figure 5-3: Adoptive Cell Therapy Initiation & Completion Year of Phase-I Clinical Trial
- Figure 6-1: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by
- Country, 2021 till 2026
- Figure 6-2: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by
- Company, 2021 till 2026
- Figure 6-3: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by
- Indication, 2021 till 2026
- Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase,
- 2021 till 2026
- Figure 8-1: Global Leukemia Incidences & Mortality (Million), 2020 & 2040
- Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
- Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
- Figure 8-4: Global Estimated Leukemia Cancer Cases, 2020-2026
- Figure 8-5: US Estimated Leukemia Cancer Cases, 2020-2026
- Figure 8-6: Europe Estimated Leukemia Cancer Cases, 2020-2026
- Figure 8-7: China Estimated Leukemia Cancer Cases, 2020-2026
- Figure 8-8: Japan Estimated Leukemia Cancer Cases, 2020-2026
- Figure 9-1: Global Lung Cancer Incidences & Mortality (Million), 2020 & 2040
- Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
- Figure 9-3: Global Estimated Lung Cancer Cases, 2020-2026



- Figure 9-4: US Estimated Lung Cancer Cases, 2020-2026
- Figure 9-5: Europe Estimated Lung Cancer Cases, 2020-2026
- Figure 9-6: China Estimated Lung Cancer Cases, 2020-2026
- Figure 9-7: Japan Estimated Lung Cancer Cases, 2020-2026
- Figure 10-1: Global Breast Cancer Incidences (Million), 2020 & 2040
- Figure 10-2: Global Breast Cancer Mortality (Million), 2020 & 2040
- Figure 10-3: Global Estimated Breast Cancer Cases, 2020-2026
- Figure 10-4: US Estimated Breast Cancer Cases, 2020-2026
- Figure 10-5: Europe Estimated Breast Cancer Cases, 2020-2026
- Figure 10-6: China Estimated Breast Cancer Cases, 2020-2026
- Figure 10-7: Japan Estimated Breast Cancer Cases, 2020-2026
- Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
- Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
- Figure 11-3: Global Estimated Colorectal Cancer Cases, 2020-2026
- Figure 11-4: US Estimated Colorectal Cancer Cases, 2020-2026
- Figure 11-5: Europe Estimated Colorectal Cancer Cases, 2020-2026
- Figure 11-6: China Estimated Colorectal Cancer Cases, 2020-2026
- Figure 11-7: Japan Estimated Colorectal Cancer Cases, 2020-2026
- Figure 12-1: Global Pancreatic Cancer Incidences, 2020 & 2040
- Figure 12-2: Global Pancreatic Cancer Mortality, 2020 & 2040
- Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
- Figure 12-4: Global Estimated Pancreatic Cancer Cases, 2020-2026
- Figure 12-5: US Estimated Pancreatic Cancer Cases, 2020-2026
- Figure 12-6: Europe Estimated Pancreatic Cancer Cases, 2020-2026
- Figure 12-7: China Estimated Pancreatic Cancer Cases, 2020-2026
- Figure 12-8: Japan Estimated Pancreatic Cancer Cases, 2020-2026
- Figure 14-1: Global Cell Therapy Market (US\$ Billion), 2020 2026
- Figure 14-2: Global Gamma Delta T Cell Therapy Market Opportunity by 1% of Total
- Cell Therapy Market (US\$ Billion), 2021-2026
- Figure 14-3: Global Gamma Delta T Cell Therapy Market Opportunity by 2% of Total
- Cell Therapy Market (US\$ Billion), 2021-2026
- Figure 14-4: Global Gamma Delta T Cell Therapy Market Opportunity by 3% of Total
- Cell Therapy Market (US\$ Billion), 2021-2026
- Figure 14-5: Global Gamma Delta T Cell Therapy Market Opportunity by 4% of Total
- Cell Therapy Market (US\$ Billion), 2021-2026
- Figure 14-6: Global Gamma Delta T Cell Therapy Market Opportunity by 5% of Total
- Cell Therapy Market (US\$ Billion), 2021-2026
- Figure 14-7: Global Gamma Delta T Cell Therapy Market Opportunity by 6% of Total



Cell Therapy Market (US\$ Billion), 2021-2026

Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US\$ Billion), 2021-2026

Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US\$ Billion), 2021-2026

Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US\$ Billion), 2021-2026

Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US\$ Billion), 2021-2026

Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040

Figure 15-2: Gamma Delta T Cells Favorable Market Parameters

Figure 15-3: Stages of Drug Development



### **List Of Tables**

#### LIST OF TABLES

- Table 6-1: Global Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
- Table 6-2: US Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
- Table 6-3: Europe Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
- Table 6-4: China Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
- Table 6-5: Japan Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
- Table 7-1: Global Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
- Table 7-2: US Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
- Table 7-3: Europe Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
- Table 7-4: China Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
- Table 7-5: Japan Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
- Table 8-1: Global Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
- Table 8-2: US Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
- Table 8-3: Europe Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
- Table 8-4: China Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
- Table 8-5: Japan Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
- Table 9-1: Global Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
- Table 9-2: US Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
- Table 9-3: Europe Estimated Adoption Rate of Gamma Delta T Cell in Colorectal



Cancer, 2021-2026

Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026

Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026

Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026

Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026

Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026

Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026

Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026



#### I would like to order

Product name: Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026

Product link: <a href="https://marketpublishers.com/r/GF3CC450BF1FEN.html">https://marketpublishers.com/r/GF3CC450BF1FEN.html</a>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/GF3CC450BF1FEN.html">https://marketpublishers.com/r/GF3CC450BF1FEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970